John P. Sheehan

Array ( [id] => 17141713 [patent_doc_number] => 20210309725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/860239 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687777 [patent_doc_number] => 20220195069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => PCSK9 INHIBITORS FOR NEUROPATHY [patent_app_type] => utility [patent_app_number] => 17/594648 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222764 [patent_doc_number] => 20200247880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => INHIBITION OF AUTISM SPECTRUM DISORDER USING DECOY ANTIGENS TO MATERNAL BRAIN-REACTIVE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/852755 [patent_app_country] => US [patent_app_date] => 2020-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16852755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17689389 [patent_doc_number] => 20220196682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => CATECHOLAMINE CONCENTRATIONS IN A BLOOD SAMPLE AND ARTERIAL HYPERTENSION STATUS IN A SUBJECT FOR A DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/594614 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 376 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17674127 [patent_doc_number] => 20220187294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => MATERIALS AND METHODS FOR DETECTING AND TREATING AUTOIMMUNE MOVEMENT DISORDERS [patent_app_type] => utility [patent_app_number] => 17/603515 [patent_app_country] => US [patent_app_date] => 2020-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391324 [patent_doc_number] => 20200332265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/846065 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190840 [patent_doc_number] => 20200231689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => TREATMENT OF MOOD AND STRESS RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/840664 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17721636 [patent_doc_number] => 20220214358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => DIAGNOSTIC FOR CHILDHOOD RISK OF AUTISM SPECTRUM DISORDER [patent_app_type] => utility [patent_app_number] => 17/601235 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16270187 [patent_doc_number] => 20200271674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease [patent_app_type] => utility [patent_app_number] => 16/829917 [patent_app_country] => US [patent_app_date] => 2020-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16829917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343610 [patent_doc_number] => 20200308260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHODS OF TREATING AL AMYLOIDOSIS [patent_app_type] => utility [patent_app_number] => 16/810319 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16251641 [patent_doc_number] => 20200261015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => METHOD FOR INDEXING COGNITIVE FUNCTION [patent_app_type] => utility [patent_app_number] => 16/794379 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341907 [patent_doc_number] => 11639381 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Treatment of headache using anti-CGRP antibodies [patent_app_type] => utility [patent_app_number] => 16/793208 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 81 [patent_no_of_words] => 35833 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16793208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792087 [patent_doc_number] => 20220251178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESHEREOF [patent_app_type] => utility [patent_app_number] => 17/608220 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18800040 [patent_doc_number] => 11833185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Anti-neurodegenerative therapeutic, method of manufacture, and use [patent_app_type] => utility [patent_app_number] => 16/788123 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 10128 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18116393 [patent_doc_number] => 11547765 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Optimized mini-dystrophin genes and expression cassettes and their use [patent_app_type] => utility [patent_app_number] => 16/787938 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 90 [patent_no_of_words] => 49786 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18800040 [patent_doc_number] => 11833185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Anti-neurodegenerative therapeutic, method of manufacture, and use [patent_app_type] => utility [patent_app_number] => 16/788123 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 10128 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16347774 [patent_doc_number] => 20200312425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT [patent_app_type] => utility [patent_app_number] => 16/779229 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963161 [patent_doc_number] => 20200165332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => IPTG-FREE INDUCTION PROCESS FOR EXPRESSION OF BIOSIMILAR RHU RANIBIZUMAB ANTIBODY FRAGMENT USING E. COLI [patent_app_type] => utility [patent_app_number] => 16/775811 [patent_app_country] => US [patent_app_date] => 2020-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4201 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16775811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341906 [patent_doc_number] => 11639380 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Acute treatment and rapid treatment of headache using anti-CGRP antibodies [patent_app_type] => utility [patent_app_number] => 16/736925 [patent_app_country] => US [patent_app_date] => 2020-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 80 [patent_no_of_words] => 36618 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156585 [patent_doc_number] => 20200216525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/736937 [patent_app_country] => US [patent_app_date] => 2020-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736937 [rel_patent_id] =>[rel_patent_doc_number] =>)